PepsiCo CEO was grilled about GLP-1s by a 13-year-old on his Q1 conference call
The 13-year-old daughter of a Jefferies analyst asked about the effect of GLP-1 oral medications during PepsiCo's most recent quarterly earnings call, as part of 'Bring your Kid to Work Day.' CEO Ramon Laguarta took the question seriously, saying his company was marketing snacks in smaller portions to target consumers with smaller appetites.
PepsiCo CEO Ramon Laguarta was no doubt expecting tough questions during the company's Q1 earnings call; what he probably wasn't expecting was to be interrogated about the effect of pharmaceuticals on the human digestive system by a 13-year-old.
Amid inquiries on revenue, tariffs, and volumes that could have comprised any other earnings call that day, Jefferies analyst Kaumil Gajrawala surprised Laguarta by letting his daughter Milena Gajrawala ask a question.
'Hey guys, it's 'Bring Your Kid to Work Day' at Jefferies. So, if you don't mind, my daughter Milena's going to ask the question,' Gajrawala said.
Far from lobbing a softball question, the 13-year-old Milena Gajrawala struck at a core issue for PepsiCo and other food companies: the threat of weight-loss inducing GLP-1 medications that curb the appetites of consumers.
'So what do you think about the launch of GLP-1 oral medications coming to market next year?' she asked.
Before answering, Laguarta said, 'That's awesome,' and then launched into a serious response that highlighted the company's 'fiber and hydration solutions.'
'We thought Milena asked a fair question and Ramon was happy to answer it. Hearing from her was a pleasant surprise on what is always a busy day," a PepsiCo spokesperson said in a statement to Fortune.
The younger Gajrawala mentioned oral GLP-1 medications, one of which—orforglipron by Eli Lilly—is already in late-stage clinical trials. Orforglipron's potential advantage is that it is an oral medication—competitor Ozempic requires regular injections—but has a similar weight-loss effect. The drug could thus supercharge the adoption of this class of medication, which helps suppress appetite and is already cutting into the profits of snack makers and other food companies.
Laguarta mentioned that another way the company is battling a potential GLP-1 slump is by emphasizing its smaller-portion snacks.
'They're eating less quantities, so our offerings in the small portions and whether it's in multipack or some other options that we provide keeps our brands in their repertoire and it's still relevant,' he said in response to Gajrawala's question.
On another earnings call that day, Gajrawala also let his son, 13-year-old Kamran Gajrawala, get in on the action. Kamran Gajrawala asked the CEO of Keurig Dr Pepper a question about Dr Pepper's new blackberry-flavored soda.
'Wow, fantastic. I think it's my first ever question from a young person, and I appreciate it, Kamran. And I hope Kamran is a big fan of Dr Pepper Blackberry,' CEO Tim Cofer said.
Wall Street has a venerable history of extracting investment wisdom from teenagers. In 2009, 15-year-old Matthew Robson, an intern at Morgan Stanley, was allowed to write a research note on how he and his friends consumed media. He reported that they didn't read newspapers and that few watched TV. None of them used Twitter, he wrote.
And earlier this year Fortune asked a 14-year-old to canvass her friends on why they stopped trusting traditional media in favor of influencers they know are unreliable. Influencers feel like trustworthy friends, whereas adults are the enemy, she found.
This story was originally featured on Fortune.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
3 Top Stocks Yielding Over 3% to Buy Right Now for Dividend Income and Upside Potential
Brookfield Infrastructure has increased its high-yielding payout every year since its formation. PepsiCo is an elite dividend stock. Prologis is growing its dividend much faster than the average dividend stock. 10 stocks we like better than PepsiCo › Dividend-paying stocks can be great investments. They can enable you to generate some passive income, providing a real return. In addition, dividend stocks have historically produced strong total returns as they've grown their earnings and shareholder payouts, driving stock price appreciation. Brookfield Infrastructure (NYSE: BIPC)(NYSE: BIP), PepsiCo (NASDAQ: PEP), and Prologis (NYSE: PLD) currently stand out among dividend stocks. The trio has excellent records of paying growing dividends. On top of that, they currently offer attractive yields of more than 3%, partly due to drops in their stock prices this year. Because of that, they offer compelling blends of dividend income and upside potential. Shares of Brookfield Infrastructure have declined by nearly 10% from their 52-week high. That slump has pushed the global infrastructure company's dividend yield up to 4.2%. The company's stock price has also slumped, even though it's having another good year, and its funds from operations (FFO) rose 5% in the first quarter, powered by inflation-driven rate increases, recently completed expansion projects, and acquisitions closed in the past year. Brookfield Infrastructure has a terrific record of paying dividends. It has increased its payment in all 16 years since its formation, growing it at a 9% compound annual rate. The company expects to continue increasing its payout in the future, targeting 5% to 9% annual growth. It sees a trio of organic growth drivers (inflation-driven rate increases, volume growth as the global economy expands, and expansion projects), increasing its FFO per share by 6% to 9% per year. On top of that, the company has an excellent record of making accretive acquisitions funded by recycling capital. It recently agreed to invest $500 million in the acquisition of Colonial Enterprises, which owns a leading U.S. refined products pipeline system. It also partnered with GATX Corporation to buy Wells Fargo's rail operating lease portfolio (consisting of 105,000 railcars) for $4.4 billion. It's also acquiring Wells Fargo's rail finance lease portfolio (23,000 railcars and 440 locomotives) in a separate deal. Brookfield estimates that acquisitions like these will help push its FFO growth rate above 10% annually. PepsiCo stock has slumped more than 25% from its 52-week high. That plunge has propelled its dividend yield to 4.4%. That's a tasty level for a company with a long history of satisfying investors' cravings for more dividend income. The food and beverage giant recently increased its dividend payment by another 5%. That extended its growth streak to 53 straight years, enough to qualify PepsiCo as an elite Dividend King. PepsiCo's stock is down due to concerns that tariffs, a slowing economy, and changing consumer tastes will impact the company's growth. On the one hand, the company is seeing some impact from those headwinds this year. It now expects its earnings per share to be at the same level as last year's, compared to the mid-single-digit growth rate it initially expected. However, the company has a resilient business and expects its growth to reaccelerate in the coming years. It has been investing heavily in the strategic transformation of its portfolio to healthier food and beverage options, including buying Poppi, Siete, and Sabra in recent quarters. These investments should pay dividends for the company in the coming years by reigniting its earnings growth engine, which should enable PepsiCo to continue increasing its dividend. Prologis stock has slumped more than 15% this year. That sell-off has helped nudge its dividend yield up to 3.7%. The leading industrial real estate investment trust (REIT) has been under some pressure due to slowing demand for warehouse space. However, the company is still performing well amid all the uncertainty. Its core FFO per share increased 11% in the first quarter as it continues to sign new leases at much higher rates compared to the price point of expiring contracts on the same space. Meanwhile, the long-term demand picture for warehouse space remains robust. "Over the long term, limited new supply and high construction costs support continued rent growth," commented CEO and co-founder Hamid Moghadam in the first-quarter earnings press release. That should enable the company to capture higher rental rates on its existing properties and continue developing new warehouses. In addition, Prologis is using some of its land to build data centers to capitalize on the growing demand for these properties to support increased digitalization and AI technology. Prologis' growth prospects should enable the REIT to continue increasing its dividend. It has grown its payout at a 13% compound annual rate over the past five years. That's faster than the S&P 500 (5%) and REIT sector average (6%). Brookfield Infrastructure, PepsiCo, and Prologis offer investors the best of both worlds. They pay dividends that yield more than double the S&P 500's average (less than 1.5%), and they have compelling upside potential from their earnings growth and an eventual recovery in their stock prices. Because of that, they could produce strong total returns from here, making them great dividend stocks to buy right now. Before you buy stock in PepsiCo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and PepsiCo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Matt DiLallo has positions in Brookfield Infrastructure, Brookfield Infrastructure Partners, PepsiCo, and Prologis. The Motley Fool has positions in and recommends Prologis. The Motley Fool recommends Brookfield Infrastructure Partners and recommends the following options: long January 2026 $90 calls on Prologis. The Motley Fool has a disclosure policy. 3 Top Stocks Yielding Over 3% to Buy Right Now for Dividend Income and Upside Potential was originally published by The Motley Fool
The Hill
14 hours ago
- The Hill
Beyond MAHA: Defeating obesity requires a new strategy
Obesity is a major health problem facing our country. According to the CDC, more than 40 percent of the U.S. population is obese, defined as having a body-mass index above 30. As astounding at that number is, it is perhaps even more surprising that nearly 20 percent of children in the U.S. are obese. Obesity leads to significant health challenges, including diabetes, stroke, cardiovascular disease and liver disease. It is clear that as a nation we must face this crisis on multiple fronts. Diet and exercise certainly help, and it's critical to ensure that people of all socioeconomic backgrounds have access to healthy foods (free of preservatives, unnecessary dyes, high fructose corn syrups etc.) and are educated in making healthy lifestyle choices. The MAHA or 'Make America Healthy Again' movement has highlighted this as one of its key objectives, and if it is successful, we should see an impact on obesity — especially in children, where diet and exercise have a huge impact on weight-related health outcomes. Obesity in adults, however, is often more challenging. Many adults with obesity struggle to lose weight, despite considerable efforts to modify their lifestyle through diet and exercise. This is because our metabolism changes as we age, and many adults who are overweight develop metabolic dysfunction or 'metabolic syndrome,' which then further perpetuates weight gain and exacerbates the situation. It has become clear in recent years that many people struggling with obesity require medical intervention – not just lifestyle intervention – and that prescriptions can substantially improve weight loss. The explosion in use of GLP-1 agonists, such as Wegovy and Zepbound, over the last two years has underscored the need for medical intervention in obese and overweight patients. Currently, about 6 percent of the U.S. population, or 15 million people, are on GLP-1 weight loss treatments, and the numbers are only expected to increase. However, while most patients lose 10 percent to 25 percent of their body weight while on a GLP-1, they do not maintain GLP-1 treatment in the long-term, with approximately 80 percent of patients discontinuing treatment within 1 year. Gastrointestinal side effects, injectable administration, and high cost have prevented long-term use of GLP-1's for weight maintenance. And unfortunately, most patients gain back all the weight after stopping the medication. Healthcare professionals and the pharmaceutical industry now recognize that obesity — like most other medical conditions — requires an 'arsenal' of treatments, rather than a one-size-fits-all approach. Post-GLP-1 weight maintenance is now widely recognized as an emerging unmet need. And patients who are not candidates for or cannot tolerate GLP-1s require alternatives. Diet and lifestyle modifications are important alongside prescription medications in fighting obesity. If we are going to be successful in overcoming this major health crisis, we need to ensure that both the pharmaceutical industry and groups like MAHA work hand in hand. Both treatment and prevention are critical in order to regain control of our nation's health. Dr. Shoshana Shendelman, Ph.D. is a scientist and entrepreneur who has founded numerous biotech companies. She is a pioneer in the development of drugs and therapeutics for rare and underserved diseases. Currently she is Vice Chair of the Advisory Board of Columbia University Medical Center and Columbia University Vagelos College of Physicians and Surgeons.
Yahoo
16 hours ago
- Yahoo
Is Celsius Holdings Stock a Buy Now?
Celsius stock is up over 50% this year. The company acquired competitor Alani Nu in April. Celsius' revenue growth is set to recover, but mostly because of its purchase of Alani Nu. 10 stocks we like better than Celsius › After massive declines in the second half of last year, Celsius Holdings (NASDAQ: CELH) stock may finally be ready for a comeback. The company's rapid growth came to a sudden halt (at least temporarily) as sluggish demand led one of its major distributors (likely PepsiCo) to dramatically scale back its orders. The beverage stock is down over 60% since its peak in early 2024. Still, it is up over 50% since the beginning of the year. The question for investors is whether that recovery signifies the beginnings of a Celsius comeback, or whether investors need to stay on the sidelines. Celsius has carved out a compelling, lucrative niche within the energy drink industry. Instead of pursuing customers like its larger competitors, Red Bull and Monster Beverage, Celsius targeted fitness enthusiasts. It also participated in clinical studies to validate the health benefits of its beverages. Celsius' beverages first became available in 2009. However, it was its distribution agreement with PepsiCo in August 2022 that helped sales take off. Since that agreement in the third quarter of 2022, quarterly revenues have increased by 75% even after the recent slowdown in sales. Additionally, that figure does not account for Celsius' takeover of Alani Nu, which occurred in the second quarter of this year. Before that purchase, Celsius also claimed approximately 11% of the market share, putting it in third place in the energy drink market. Still, investors should remember that it leads the health and fitness-oriented niche in the market, which will likely make it a major force in this industry. Amid the stock's partial recovery, Celsius sells at a price-to-earnings (P/E) ratio of 127. Nonetheless, since it is recovering from last year's slump, the forward P/E ratio of 50 may better reflect the company's valuation, a level coming off historical lows. It is also well below the forward P/E ratio of 125 from the stock's peak in early 2024. That forward multiple arguably brings the stock price more in line with its current growth. Unfortunately, investors may still balk at Celsius' valuation as they brace for slower growth. In the first quarter of 2025, revenue of $329 million dropped by 7% yearly. That's a dramatic improvement over the 31% decline in Q3. Still, it is well below the 102% revenue gain in 2023. The falling revenue also led to a comprehensive income in Q1 of $37 million, well below the $63 million in the year-ago quarter. Revenue growth should improve in the near term due in part to the Alani Nu takeover. In 2025, analysts forecast 60% revenue growth. But once Celsius benefits from that one-time bump, they expect the revenue increase rate to slow to 21% in 2026. Knowing that, the most significant hope for bulls may lie in the company's potential internationally, where 96% of the world's population resides. Even though international sales made up 7% of revenue in Q1 2025, that part of the market grew revenue by 41% annually. Moreover, that revenue share was only 4% one year ago. Assuming it can continue to increase the proportion of international sales significantly, Celsius stock could deliver higher returns if revenue growth abroad remains strong. Over the long term, Celsius stock likely remains a buy. Admittedly, the 50 forward P/E ratio could point to some overvaluation in the near term. Furthermore, the immediate recovery in revenue will probably happen because of the buyout of Alani Nu, rather than an organic increase in Celsius brand products. Nonetheless, the 21% forecasted revenue increase in 2026 is an indication that demand will rise over time. Additionally, even though international growth will take some time, sales outside of North America are likely to become the company's primary revenue driver over time. Such potential indicates that Celsius' growth story is far from over, meaning its stock could still be positioned for huge gains. Before you buy stock in Celsius, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Celsius wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Will Healy has positions in Celsius. The Motley Fool has positions in and recommends Celsius and Monster Beverage. The Motley Fool has a disclosure policy. Is Celsius Holdings Stock a Buy Now? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
